Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Telesis Bio Inc

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

Translate Bio Up on Vaccine Agreement Expansion With Sanofi

Inovio Pharmaceuticals

Major market benchmarks settled for modest gains on Tuesday.

The Stock Market's Coronavirus Vaccine Hopes Sent These 2 Stocks Soaring

Sanofi SA which is in the race to develop a vaccine for SARS-CoV-2, which causes COVID-19, is unveiling an accelerated timeline for the vaccine program it is pursuing with GlaxoSmithKline plc

Sanofi Accelerates Coronavirus Vaccine Timeline, Says Approval Could Come In First Half Of 2021

The company's collaboration with Sanofi is shifting into a higher gear.

Here's Why Translate Bio Stock Is Rocketing Higher Today

Shares of the small-cap mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO) were ripping higher Tuesday.

Why Shares of Translate Bio Are Surging Higher

Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. 
The companies are already developing a mRNA vaccine candidate to combat COVID-19.

Sanofi Expands Agreement With Translate Bio for mRNA Vaccines

Sanofi S.A. (NASDAQ: SNY) and Translate Bio Inc.

Why the Sanofi and Translate Bio Deal Is Win-Win

Translate Bio stock rocketed Tuesday after the biotech inked a deal with Sanofi to develop vaccines for all infectious diseases. Before, the companies had a deal for five vaccines.

Small Biotech Rockets 60% On Sanofi's $425 Million Vaccines Bet

French drugmaker Sanofi has agreed a potential $2 billion deal with U.S. biotech company Translate Bio to make vaccines, expanding their collaboration in development of an inoculation against COVID-19.

Sanofi clinches $2 billion vaccines deal with Translate Bio

uniQure

Did Sanofi Free Up Cash To Acquire uniQure?

Mylan

Pfizer

Hydroxychloroquine as a COVID-19 treatment has been a controversial subject -- and the debate continues.

Is Hydroxychloroquine a Cure for COVID-19?

Hertz

Royal Caribbean Cruises

Regeneron Pharmaceuticals

There are two critical factors to the economic and market recovery. Each got positive shots in the arm this week.

2 Events Propelling the Market Higher This Week, and Possibly Beyond

Sanofi (SNY) plans to invest almost $690 billion to develop a new production site and research center in France with both dedicated to vaccines.

Sanofi (SNY) to Create Dedicated Vaccine Center in France

Sanofi S.A.’s (NASDAQ: SNY) announcement that it would be investing in a COVID-19 vaccine production site in France gave shares a boost early Tuesday.

Meet Sanofi’s Big New Investment Into a COVID-19 Vaccine

In the latest trading session, Sanofi (SNY) closed at $50.59, marking a +1.28% move from the previous day.

Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know

In a June 11 article for GuruFocus, I looked at the R&D efforts underway at the top five spenders in the pharmaceutical industry last year.

Sanofi Leads Second Tier of R&D Spenders

The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.

Sanofi and Denali Halt Clinical Trials of Alzheimer Drug

Sanofi (SNY) closed at $50.85 in the latest trading session, marking a +0.08% move from the prior day.

Sanofi (SNY) Gains As Market Dips: What You Should Know

Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease

The data used in the study could not be verified by independent auditors.

Influential Hydroxychloroquine COVID-19 Study Retracted by Authors

Results of a post-exposure prophylaxis study with the old malaria drug were a real letdown.

Study Shows Hydroxychloroquine Can't Prevent Coronavirus Infection

Bristol-Myers

Novo Nordisk

Takeda Pharmaceutical

Zoetis

Pharmaceutical stocks dipped by a single-digit percentage in the first five months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Why These 5 Pharma Stocks Are Outplaying 90% Of The Stock Market

Despite a global pandemic, Sanofi SA (NASDAQ: SNY) is able to continue its research and development — and it is "essential" to continue showing success in trials, CEO Paul Hudson said on CNBC's "Squawk Box.

Sanofi's CEO On Cancer Research, Coronavirus Vaccine Progress

The malaria drug is quickly falling out of favor with the medical community as a potential treatment for the disease.

Sanofi Stops Supplying Hydroxychloroquine to COVID-19 Patients in Clinical Trials

Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.

News for Sanofi Stock (SNY)